Currently, the only FDA-approved nanomedicine for various other cancer treatments includes; Doxil (liposomal doxorubicin), Onivyde (liposomal irinotecan), Abraxane (albumin-particle bound paclitaxel), Eligard (leuprolide acetate), and Vyxeos (liposomal cytarabine and daunorubicin) with none specific to HCC. This evidence concerns the gene ALB and cancer.